Lumos Labs has gained US Food and Drug Administration (FDA) clearance for LumosityRx, a prescription digital therapeutic (PDT) that aims to improve attention span in adult patients with attention deficit hyperactivity disorder (ADHD) at a time where incidence of the condition in the US is on the rise.

LumosityRx is indicated for patients aged between 22 and 55 with primarily inattentive or combined‐type ADHD. The PDT comes in the form of a mobile app that delivers clinically validated versions of 13 cognitive training games from Lumos Labs’ Lumosity brain training platform that target cognitive processes that contribute to attention function.

A 2024 report by the US Centers for Disease Control and Prevention (CDC) deemed paediatric ADHD a “rising public health concern”. Using data from the 2022 National Survey of Children’s Health (NSCH), the research found that 7.1 million children and adolescents in the US received an ADHD diagnosis in 2022 – a million more of this demographic than in 2016.